Is leuprolide appropriate for refractory premenstrual dysphoric disorder (PMDD) or severe premenstrual syndrome (PMS), and what are the recommended dosing and add‑back therapy?

Leuprolide for Refractory PMDD/PMS

Leuprolide (GnRH agonist) is highly effective for refractory PMDD and severe PMS when first-line treatments (SSRIs and combined oral contraceptives) have failed, but must be administered with hormonal add-back therapy to prevent bone loss and manage menopausal symptoms.

Evidence for Efficacy

Leuprolide works by suppressing ovarian function and eliminating the hormonal fluctuations that trigger PMDD symptoms. The evidence is compelling:

• Landmark studies demonstrate that ovarian suppression with leuprolide eliminates PMDD symptoms entirely 1, 2. When estradiol or progesterone is reintroduced during continued leuprolide treatment, symptoms recur in women with PMDD but not in healthy controls, confirming that PMDD represents an abnormal response to normal hormonal changes 1, 2.

• Leuprolide reduces both behavioral and physical symptoms to follicular phase levels in women without severe premenstrual depression 3. However, women with severe premenstrual depression show no improvement, making depression severity assessment critical before initiating treatment 3, 4.

• Symptom improvement is progressive and may not occur until after several months of treatment 5, 4. This delayed response is important for patient counseling.

Dosing Regimen

Standard dosing: Depot leuprolide 3.75 mg intramuscularly monthly 5, 3, 4. The daily subcutaneous formulation (1 mg/0.2 mL daily) 6 is FDA-approved for prostate cancer, not PMDD, making the depot formulation more practical for this indication.

Mandatory Add-Back Therapy

Hormonal add-back therapy is essential and should be initiated within the first treatment cycle 5:

First-Line Add-Back Protocol:

• Conjugated equine estrogen 0.625 mg daily (Monday through Saturday)
• Medroxyprogesterone acetate (MPA) 10 mg daily for 10 days after cycles 4,8, and 12 (every 4th cycle) 5

This regimen:

• Prevents bone density loss (though some 3.7% decrease may still occur at 12 months) 5
• Protects the endometrium adequately with quarterly progestin 5
• Avoids adverse lipid changes 5
• Maintains symptom control with progressive improvement over 12 months 5

Alternative Add-Back Options:

If the above regimen is not tolerated, consider transdermal estradiol (50-100 μg patches) with cyclic oral progesterone (200 mg for 12-14 days every 28 days) 7. Micronized progesterone is preferred over synthetic progestins when possible due to lower cardiovascular risk 7.

Critical Patient Selection Criteria

Screen for severe premenstrual depression before prescribing leuprolide 3, 4:

• Women with moderate premenstrual depression improve but remain symptomatic
• Women with severe premenstrual depression show no improvement on any measure
• Women without premenstrual depression respond best with lowest adverse event rates 3

Contraindications from FDA labeling 6:

• Pregnancy (causes fetal harm)
• Women desiring fertility (may impair fertility in both sexes)
• Congenital long QT syndrome
• Uncontrolled cardiovascular disease

Monitoring Requirements

• Endometrial biopsy after 12 cycles to confirm adequate endometrial protection 5
• Bone density assessment (quantitative CT or DEXA) at 12 months 5
• Lipid profile periodically 7
• ECG and electrolytes in patients with cardiovascular risk factors 6

Duration of Treatment

Treatment can be continued long-term (12+ months) with appropriate add-back therapy and monitoring 5. The study demonstrating safety used 12 monthly cycles with quarterly progestin 5.

Common Pitfalls to Avoid

1. Starting leuprolide without add-back therapy - This causes severe menopausal symptoms and bone loss
2. Inadequate progestin dosing - Must use sufficient dose (10 mg MPA for 10 days every 4th cycle minimum) for endometrial protection 5
3. Prescribing to women with severe depression - These patients do not respond 3, 4
4. Expecting immediate results - Efficacy develops over several months 4
5. Failing to counsel about fertility effects - Leuprolide may reduce fertility 6

Position in Treatment Algorithm

Leuprolide with add-back therapy should be reserved for refractory cases after failure of 8, 9:

1. First-line: SSRIs (continuous or luteal phase)
2. Second-line: Combined oral contraceptives containing drospirenone

The most recent comprehensive reviews position GnRH agonists as effective for refractory cases 8, with surgical intervention (bilateral oophorectomy) reserved for those who fail all medical management.